Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus capecitabine for recurrent or metastatic head and neck squamous cell carcinoma
ISRCTN14555104Phase 2Completed
- Sponsor
- Department of Oncology, Herlev Hospital
- Start
- Sep 2000
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and capecitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by Department of Oncology, Herlev Hospital. Primary endpoints: Response rate and Toxicity. Started Sep 2000; status: completed.
02
Drugs
paclitaxelcapecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN14555104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14555104.